MedTrace Logo

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

NCT03204929 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-03-17

No results posted yet for this study

Summary

Multicenter, open-label dose-escalation study

Conditions

  • Parkinson Disease

Interventions

DRUG

Cu(II)ATSM

copper-containing synthetic small molecule

Sponsors & Collaborators

  • Collaborative Medicinal Development Pty Limited

    lead INDUSTRY

Principal Investigators

  • Andrew Evans, MD · Melbourne Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2019-11-30
Completion
2020-02-29
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204929 on ClinicalTrials.gov